– Late-breaking Phase III results show subcutaneous injection was non-inferior to intravenous infusion based on Ocrevus levels in the blood over 12 weeks – – Ocrevus subcutaneous injection was ...

Of particular concern are patients with severe lipoatrophy of the extremities. These individuals or their caregivers may need to search for sites with more subcutaneous fat to avoid injection into the ...

Subcutaneous ocrelizumab (SC OCR) maintains a safety profile similar to intravenous administration in multiple sclerosis patients. A 920 mg SC OCR dose was identified as optimal, with mild to moderate ...

As with other drugs, icatibant can cause side effects, such as dizziness and injection reactions. If icatibant side effects become difficult to tolerate, talk with your doctor or pharmacist. Icatibant ...

Leqvio (inclisiran) may cause injection site reactions, including bruising, pain, discoloration, itchiness, and a burning or prickling sensation at the injection site. In addition to injection site ...

– Ocrevus Zunovo™ has the potential to expand treatment options to centers without IV infrastructure or with IV constraints, like at a doctor's office – – This approval is backed by a decade of proven ...

At all doses and formulations evaluated in Part 1 of the trial, Z-1018 was well-tolerated and demonstrated a favorable tolerability profile, including lower solicited local and systemic post-injection ...

Approval Granted with Competitive Generic Therapy Eligibility for 100mg/5mL and 200mg/10mL Strengths; Provides Eligibility for 180 Days of Exclusivity Viatris Chief R&D Officer Philippe Martin said, ...

Basel, 16 September 2024 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced that the United States Food and Drug Administration (U.S. FDA) has approved OCREVUS ZUNOVO™ (ocrelizumab & hyaluronidase-ocsq) ...